The discovery of circulating nucleic acids in the 1940s opened up new possibilities for the non-invasive detection, monitoring and screening of various human disorders. Several tumour markers that enable early cancer detection or tumour behaviour prediction have been detected in the plasma of cancer patients. Maternal plasma analysis can be used to detect certain fetal abnormalities, with the quantification of cell-free nucleic acids used to screen for several pregnancy-associated disorders. Some other applications are in transplant monitoring and graft rejection assessment, and in certain medical emergencies such as trauma and burn severity stratification. Many studies have yielded promising results in this field, but the techniques have yet to be applied in routine clinical practice. Large-scale studies using similar technologies and a broad spectrum of patients are still needed to verify the results of the various studies.

Department of Otorhinolaryngology and Head and Neck Surgery Institute of Postgraduate Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Mandel P., Metais P. Les acides nucleiques du plasma sanguin chez l homme. C. R. Seances Soc. Biol. Fil. 1948;142:241–243. PubMed

Tan E.M., Schur P.H., Carr R.I., Kunkel H.G. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J. Clin. Invest. 1966;45:1732–1740. doi: 10.1172/JCI105479. PubMed DOI PMC

Ayala W., Moore L.V., Hess E.L. The purple color reaction given by diphenylamine reagent. I. with normal and rheumatic fever sera. J. Clin. Invest. 1951;30:781–785. doi: 10.1172/JCI102492. PubMed DOI PMC

Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer. Res. 1977;37:646–650. PubMed

Sorenson G.D., Pribish D.M., Valone F.H., Memoli V.A., Bzik D.J., Yao S.L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer. Epidemiol. Biomarkers Prev. 1994;3:67–71. PubMed

Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol. 1994;86:774–779. doi: 10.1111/j.1365-2141.1994.tb04828.x. PubMed DOI

Lo Y.M. Circulating nucleic acids in plasma and serum: an overview. Ann. N. Y. Acad. Sci. 2001;945:1–7. PubMed

Johnson P.J., Lo Y.M. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin. Chem. 2002;48:1186–1193. PubMed

Swarup V., Rajeswari M.R. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 2007;581:795–799. doi: 10.1016/j.febslet.2007.01.051. PubMed DOI

Sorenson G.D., Porter D.M., Barth R.J., Memoli V.A., Rhodes C.H., Karagas M. Detection of mutated K-ras2 sequences in plasma from patients with pancreatic carcinoma in comparsion with the CA 19-9 assay. J. Int. Soc. Oncodev. Biol. Med. 1997;18:66.

Chen X., Bonnefoi H., Diebold-Berger S., Lyautey J., Lederrey C., Faltin-Traub E., Stroun M., Anker P. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin. Cancer Res. 1999;5:2297–2303. PubMed

Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 1996;2:1035–1037. doi: 10.1038/nm0996-1035. PubMed DOI

Frost P.G., Lachmann P.J. The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin. Exp. Immunol. 1968;3:447–455. PubMed PMC

Giacona B., Ruben C., Iczkowski A., Roos B., Porter M., Sorenson D. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17:89–97. doi: 10.1097/00006676-199807000-00012. PubMed DOI

Wieczorek J., Rhyner C., Block H. Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans. Proc. Natl. Acad. Sci. U.S.A. 1985;82:3455–3459. doi: 10.1073/pnas.82.10.3455. PubMed DOI PMC

Hasselmann O., Rappl G., Tilgen W., Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin. Chem. 2001;47:1488–1489. PubMed

Chelobanov P., Laktionov P., Kharkova V., Rykova Y., Vlassov V. Isolation of nucleic acid binding proteins: an approach for isolation of cell surface, nucleic acid binding proteins. Ann. N.Y. Acad. Sci. 2004;1022:239–243. doi: 10.1196/annals.1318.037. PubMed DOI

Holdenrieder S., Holubec L., Jr., Topolcan O., Finek J., Stieber P. Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res. 2005;25:1795–1801. PubMed

El-Hefnawy T., Raja S., Kelly L., Bigbee W.L., Kirkwood J.M., Luketich J.D., Godfrey T.E. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin. Chem. 2004;50:564–573. doi: 10.1373/clinchem.2003.028506. PubMed DOI

Wong B.C., Chan K.C., Chan A.T., Leung S.F., Chan L.Y., Chow K.C., Lo Y.M. Reduced plasma RNA integrity in nasopharyngeal carcinoma patients. Clin. Cancer. Res. 2006;12:2512–2516. doi: 10.1158/1078-0432.CCR-05-2572. PubMed DOI

Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer. 2007;120:1046–1054. doi: 10.1002/ijc.22394. PubMed DOI PMC

Coppola V., de Maria R., Bonci D. MicroRNAs and prostate cancer. Endocr. Relat. Cancer. 2010;29:1–17. doi: 10.1677/ERC-09-0172. PubMed DOI

Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., Liu C.G., Calin G.A., Croce C.M., Harris C.C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–436. doi: 10.1001/jama.299.4.425. PubMed DOI PMC

Gormally E., Vineis P., Matullo G., Veglia F., Caboux E., Le Roux E., Peluso M., Garte S., Guarrera S., Munnia A., Airoldi L., Autrup H., Malaveille C., Dunning A., Overvad K., Tjonneland A., Lund E., Clavel-Chapelon F., Boeing H., Trichopoulou A., Palli D., Krogh V., Tumino R., Panico S., Bueno-de-Mesquita H.B., Peeters P.H., Pera G., Martinez C., Dorronsoro M., Barricarte A., Navarro C., Quiros J.R., Hallmans G., Day N.E., Key T.J., Saracci R., Kaaks R., Riboli E., Hainaut P. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 2006;66:6871–6876. doi: 10.1158/0008-5472.CAN-05-4556. PubMed DOI

McHale C.M., Lan Q., Corso C., Li G., Zhang L., Vermeulen R., Curry J.D., Shen M., Turakulov R., Higuchi R., Germer S., Yin S., Rothman N., Smith M.T. Chromosome translocations in workers exposed to benzene. J. Natl. Cancer. Inst. Monogr. 2008;39:74–77. doi: 10.1093/jncimonographs/lgn010. PubMed DOI

Scarpato R., Antonelli A., Ballardin M., Cipollini M., Fallahi P., Tomei A., Traino C., Barale R. Analysis of chromosome damage in circulating lymphocytes of radiological workers affected by thyroid nodules. Mutat. Res. 2006;606:21–26. PubMed

Taback B., O’Day S.J., Boasberg P.D., Shu S., Fournier P., Elashoff R., Wang H.J., Hoon D.S. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J. Natl. Cancer. Inst. 2004;96:152–156. PubMed PMC

Maguire P., Holmberg K., Kost-Alimova M., Imreh S., Skoog L., Lindblom A. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12. Int. J. Mol. Med. 2005;16:135–141. PubMed

Chan K.C., Lai P.B., Mok T.S., Chan H.L., Ding C., Yeung S.W., Lo Y.M. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin. Chem. 2008;54:1528–1536. doi: 10.1373/clinchem.2008.104653. PubMed DOI

Pan S.Y., Xie E.F., Shu Y.Q., Gao L., Zhang L.X., Chen D., Chen J.B., Zhao W.J., Mu Y., Zhang J.N. Methylation quantification of adenomatous polyposis coli (APC) gene promoter in plasma of lung cancer patients. Ai Zheng. 2009;28:384–389. PubMed

Van der Auwera I., Elst H.J., Van Laere S.J., Maes H., Huget P., van Dam P., Van Marck E.A., Vermeulen P.B., Dirix L.Y. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer. 2009;100:1277–1286. doi: 10.1038/sj.bjc.6605013. PubMed DOI PMC

Righini C.A., de Fraipont F., Reyt E., Favrot M.C. Aberrant methylation of tumor suppressor genes in head and neck squamous cell carcinoma: is it clinically relevant? Bull. Cancer. 2007;94:191–197. PubMed

Jubb A.M., Quirke P., Oates A.J. DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility. Ann. N.Y. Acad. Sci. 2003;983:251–267. doi: 10.1111/j.1749-6632.2003.tb05980.x. PubMed DOI

Grützmann R., Molnar B., Pilarsky C., Habermann J.K., Schlag P.M., Saeger H.D., Miehlke S., Stolz T., Model F., Roblick U.J., Bruch H.P., Koch R., Liebenberg V., Devos T., Song X., Day R.H., Sledziewski A.Z., Lofton-Day C. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008;3:e3759. doi: 10.1371/journal.pone.0003759. PubMed DOI PMC

Kawakami K., Brabender J., Lord R.V., Groshen S., Greenwald B.D., Krasna M.J., Yin J., Fleisher A.S., Abraham J.M., Beer D.G., Sidransky D., Huss H.T., Demeester T.R., Eads C., Laird P.W., Ilson D.H., Kelsen D.P., Harpole D., Moore M.B., Danenberg K.D., Danenberg P.V., Meltzer S.J. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 2000;92:1805–1811. doi: 10.1093/jnci/92.22.1805. PubMed DOI

Melnikov A., Scholtens D., Godwin A., Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J. Mol. Diagn. 2009;11:60–65. doi: 10.2353/jmoldx.2009.080072. PubMed DOI PMC

Wieczorek A.J., Sitaramam V., Machleidt W., Rhyner K., Perruchoud A.P., Block L.H. Diagnostic and prognostic value of RNA-proteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker. Cancer Res. 1987;47:6407–6412. PubMed

Wong S.C., Lo S.F., Cheung M.T., Ng K.O., Tse C.W., Lai B.S., Lee K.C., Lo Y.M. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin. Cancer Res. 2004;10:1613–1617. doi: 10.1158/1078-0432.CCR-1168-3. PubMed DOI

Chu D.C., Chuang C.K., Liou Y.F., Tzou R.D., Lee H.C., Sun C.F. The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma. Ann. N. Y. Acad. Sci. 2004;1022:157–162. doi: 10.1196/annals.1318.026. PubMed DOI

Chen X.Q., Bonnefoi H., Pelte M.F., Lyautey J., Lederrey C., Movarekhi S., Schaeffer P., Mulcahy H.E., Meyer P., Stroun M., Anker P. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin. Cancer Res. 2000;6:3823–3826. PubMed

Sueoka E., Sueoka N., Iwanaga K., Sato A., Suga K., Hayashi S., Nagasawa K., Nakachi K. Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer. 2005;48:77–83. doi: 10.1016/j.lungcan.2004.10.007. PubMed DOI

Silva J.M., Rodriguez R., Garcia J.M., Munoz C., Silva J., Dominguez G., Provencio M., Espana P., Bonilla F. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 2002;50:530–534. doi: 10.1136/gut.50.4.530. PubMed DOI PMC

Johnstone R.M. Revisiting the road to the discovery of exosomes. Blood Cells Mol. Dis. 2005;34:214–219. doi: 10.1016/j.bcmd.2005.03.002. PubMed DOI

Papadopoulou E., Davilas E., Sotiriou V., Koliopanos A., Aggelakis F., Dardoufas K., Agnanti N.J., Karydas I., Nasioulas G. Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer. Oncol. Res. 2004;14:439–445. PubMed

Hasselmann D.O., Rappl G., Rossler M., Ugurel S., Tilgen W., Reinhold U. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol. Rep. 2001;8:115–118. PubMed

Miura N., Shiota G., Nakagawa T., Maeda Y., Sano A., Marumoto A., Kishimoto Y., Murawaki Y., Hasegawa J. Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma. Oncology. 2003;64:430–434. doi: 10.1159/000070303. PubMed DOI

O’Driscoll L. Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers. Anticancer Res. 2007;27:1257–1265. PubMed

Fleischhacker M., Beinert T., Ermitsch M., Seferi D., Possinger K., Engelmann C., Jandrig B. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann. N.Y. Acad. Sci. 2001;945:179–188. PubMed

Li Y., Elashoff D., Oh M., Sinha U., St John M.A., Zhou X., Abemayor E., Wong D.T. Serum circulating human mRNA profiling and its utility for oral cancer detection. J. Clin. Oncol. 2006;24:1754–1760. doi: 10.1200/JCO.2005.03.7598. PubMed DOI

O’Driscoll L., Kenny E., Mehta J.P., Doolan P., Joyce H., Gammell P., Hill A., O’Daly B., O’Gorman D., Clynes M. Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics. 2008;5:94–104. PubMed

Galamb O., Sipos F., Spisak S., Galamb B., Krenacs T., Valcz G., Tulassay Z., Molnar B. Potential biomarkers of colorectal adenomadysplasia-carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol. 2009;31:19–29. PubMed PMC

Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim. Biophys. Acta. 2007;1775:181–232. PubMed

Croce C. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009;10:704–714. doi: 10.1038/nrg2634. PubMed DOI PMC

Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–198. doi: 10.1016/j.ccr.2006.01.025. PubMed DOI

Liu, X., Chen, Z., Yu, J., Xia, J. and Zhou, X. MicroRNA profiling and head and neck cancer. Comp. Funct. Genomics (2009) DOI: 10.1155/2009/837514. PubMed PMC

Simpson R.J., Lim J.W., Moritz R.L., Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics. 2009;6:267–283. doi: 10.1586/epr.09.17. PubMed DOI

Logozzi M., De Milito A., Lugini L., Borghi M., Calabrò L., Spada M., Perdicchio M., Marino M.L., Federici C., Iessi E., Brambilla D., Venturi G., Lozupone F., Santinami M., Huber V., Maio M., Rivoltini L., Fais S. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009;4:e5219. doi: 10.1371/journal.pone.0005219. PubMed DOI PMC

Nilsson J., Skog J., Nordstrand A., Baranov V., Mincheva-Nilsson L., Breakefield X.O., Widmark A. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer. 2009;100:1603–1607. doi: 10.1038/sj.bjc.6605058. PubMed DOI PMC

Shao Y., Zhang Y., Li H., Gao Y., Feng X., Wu L., Cui J., Cheng G., Hu B., Hu F., Ernberg I., Zeng X. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 2004;24:4059–4066. PubMed

Ayadi W., Karray-Hakim H., Feki L., Khabir A., Boudawara T., Ghorbel A., Daoud J., Frikha M., Hammami A. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. J. Med. Virol. 2009;81:1412–1421. doi: 10.1002/jmv.21532. PubMed DOI

Yang J., Liu W., Tsang C., Yip M., Tam F., Wong C., Ng Y., Ngan Y. Quantification of human papillomavirus DNA in the plasma of patients with cervical cancer. Int. J. Gynecol. Cancer. 2004;14:903–910. doi: 10.1111/j.1048-891X.2004.014528.x. PubMed DOI

Capone B., Pai I., Koch M., Gillison L., Danish N., Westra H., Daniel R., Shah V., Sidransky D. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 2000;6:4171–4175. PubMed

Lo Y.M., Corbetta N., Chamberlain P.F., Rai V., Sargent I.L., Redman C.W., Wainscoat J.S. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–487. doi: 10.1016/S0140-6736(97)02174-0. PubMed DOI

Costa J.M., Benachi A., Gautier E. New strategy for prenatal diagnosis of X-linked disorders. N. Engl. J. Med. 2002;346:1502. doi: 10.1056/NEJM200205093461918. PubMed DOI

Chiu R.W., Lau T.K., Cheung P.T., Gong Z.Q., Leung T.N., Lo Y.M. Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study. Clin. Chem. 2002;48:778–780. PubMed

Leung T.N., Zhang J., Lau T.K., Chan L.Y., Lo Y.M. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeklampsia. Clin. Chem. 2002;47:137–139. PubMed

Lau T.K., Lo K.W., Chan L.Y., Leung T.Y., Lo Y.M. Cell-free fetal deoxyribonucleic acid in maternal circulation as a marker of fetal-maternal hemorrhage in patients undergoing external cephalic version near term. Am. J. Obstet. Gynecol. 2000;183:712–716. doi: 10.1067/mob.2000.106582. PubMed DOI

Saito H., Sekizawa A., Morimoto T., Suzuki M., Yanaihara T. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet. 2000;356:1170. doi: 10.1016/S0140-6736(00)02767-7. PubMed DOI

Amicucci P., Gennarelli M., Novelli G., Dallapiccola B. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin. Chem. 2000;46:301–302. PubMed

González-González C., Trujillo J., Rodríguez de Alba M., García-Hoyos M., Lorda-Sánchez I., Díaz-Recasens J., Ayuso C., Ramos C. Huntington disease-unaffected fetus diagnosed from maternal plasma using QF-PCR. Prenat. Diagn. 2003;23:232–234. doi: 10.1002/pd.570. PubMed DOI

Chiu W., Lau K., Cheung T., Gong Q., Leung N., Lo M. Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study. Clin. Chem. 2002;48:778–780. PubMed

González-González C., García-Hoyos M., Trujillo J., Rodríguez de Alba M., Lorda-Sánchez I., Díaz-Recasens J., Gallardo E., Ayuso C., Ramos C. Prenatal detection of a cystic fibrosis mutation in fetal DNA from maternal plasma. Prenat. Diagn. 2002;22:946–948. doi: 10.1002/pd.439. PubMed DOI

Chiu W., Lau K., Leung N., Chow C., Chui H., Lo M. Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. Lancet. 2002;360:998–1000. doi: 10.1016/S0140-6736(02)11086-5. PubMed DOI

Tong Y.K., Lo Y.M. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin. Chim. Acta. 2006;363:187–196. doi: 10.1016/j.cccn.2005.05.048. PubMed DOI

Tsui N.B., Dennis, Lo Y.M. Placental RNA in maternal plasma: toward noninvasive fetal gene expression profiling. Ann. N. Y. Acad. Sci. 2006;1075:96–102. doi: 10.1196/annals.1368.012. PubMed DOI

Vlassov V.V., Laktionov P.P., Rykova E.Y. Extracellular nucleic acids. Bioessays. 2007;29:654–667. doi: 10.1002/bies.20604. PubMed DOI

Rainer T.H., Wong L.K., Lam W., Yuen E., Lam N.Y., Metreweli C., Lo Y.M. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin. Chem. 2003;49:562–569. doi: 10.1373/49.4.562. PubMed DOI

Rainer T.H., Lam N.Y., Tsui N.B., Ng E.K., Chiu R.W., Joynt G.M., Lo Y.M. Effects of filtration on glyceraldehyde-3-phosphate dehydrogenase mRNA in the plasma of trauma patients and healthy individuals. Clin. Chem. 2004;50:206–208. doi: 10.1373/clinchem.2003.022533. PubMed DOI

Fox A., Gal S., Fisher N., Smythe J., Wainscoat J., Tyler M.P., Watt S.M., Harris A.L. Quantification of circulating cell-free plasma DNA and endothelial gene RNA in patients with burns and relation to acute thermal injury. Burns. 2008;34:809–816. doi: 10.1016/j.burns.2007.10.003. PubMed DOI

Hamaoui K., Butt A., Powrie J., Swaminathan R. Concentration of circulating rhodopsin mRNA in diabetic retinopathy. Clin. Chem. 2004;50:2152–2155. doi: 10.1373/clinchem.2004.037168. PubMed DOI

Swaminathan R., Butt N. Circulating nucleic acids in plasma and serum: recent developments. Ann. N. Y. Acad. Sci. 2006;1075:1–9. doi: 10.1196/annals.1368.001. PubMed DOI

Vasavda N., Ulug P., Kondaveeti S., Ramasamy K., Sugai T., Cheung G., Rees C., Awogbade M., Bannister S., Cunningham J., Menzel S., Thein L. Circulating DNA: a potential marker of sickle cell crisis. Br. J. Haematol. 2007;139:331–336. doi: 10.1111/j.1365-2141.2007.06775.x. PubMed DOI

Gadi V.K., Nelson J.L., Boespflug N.D., Guthrie K.A., Kuhr C.S. Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection. Clin. Chem. 2006;52:379–382. doi: 10.1373/clinchem.2005.058974. PubMed DOI

Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987;162:156–159. doi: 10.1016/0003-2697(87)90021-2. PubMed DOI

Chan A.T., Lo Y.M., Zee B., Chan L.Y., Ma B.B., Leung S.F., Mo F., Lai M., Ho S., Huang D.P., Johnson P.J. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl. Cancer Inst. 2002;94:1614–1619. PubMed

Zhong X.Y., Holzgreve W., Hahn S. Risk free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell free fetal DNA in maternal plasma. Swiss Med. Wkly. 2001;131:70–74. PubMed

Mueller D.W., Rehli M., Bosserhoff A.K. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 2009;129:1740–1751. doi: 10.1038/jid.2008.452. PubMed DOI

Collado M., Garcia V., Garcia J.M., Alonso I., Lombardia L., Diaz-Uriarte R., Fernandez L.A., Zaballos A., Bonilla F., Serrano M. Genomic profiling of circulating plasma RNA for the analysis of cancer. Clin. Chem. 2007;53:1860–1863. doi: 10.1373/clinchem.2007.089201. PubMed DOI

Zimmermann B.G., Grill S., Holzgreve W., Zhoní X.Y., Jackson L.G., Hahn S. Digital PCR: a powerful new tool for noninvasive prenatal diagnosis? Prenat. Diagn. 2008;28:1087–1093. PubMed

Lo Y.M., Lun F.M., Chan K.C., Taji N.B., Chiny K.C., Lau T.K., Lejny T.Y., Zee B.C., Cantor C.R., Chiu R.W. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc. Natl. Acad. Sci. U.S.A. 2007;104:13116–13121. doi: 10.1073/pnas.0705765104. PubMed DOI PMC

Tong Y.K., Ding C., Chiu R.W., Gerovassili A., Chim S.S., Lejny T.Y., Lejny T.N., Lau T.K., Nicolaides K.H., Lo Y.M. Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. Clin. Chem. 2006;52:2194–2202. doi: 10.1373/clinchem.2006.076851. PubMed DOI

Diehl F., Li M., He Y., Kinzler K.W., Vogelstein B., Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat. Methods. 2006;3:551–559. doi: 10.1038/nmeth898. PubMed DOI

Spurgeon S.L., Jones R.C., Ramakrishnan R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One. 2008;3:e1662. doi: 10.1371/journal.pone.0001662. PubMed DOI PMC

Fan H., Quake S. Detection of aneuploidy with digital polymerase chain reaction. Anal. Chem. 2007;79:7576–7579. doi: 10.1021/ac0709394. PubMed DOI

Fan H.C., Blumenfeld Y.J., Chitkara U., Hudgins L., Quake S.R. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc. Natl. Acad. Sci. U.S.A. 2008;105:16266–16271. doi: 10.1073/pnas.0808319105. PubMed DOI PMC

Microarray analysis of serum mRNA in patients with head and neck squamous cell carcinoma at whole-genome scale